PerkinElmer, Inc.
Mar 25, 2011
PDF

PerkinElmer Highlights New Drug Discovery and Life Science Research Solutions at the Society for Biomolecular Sciences (SBS) 2011 Conference

ORLANDO, FL –At the Society for Biomolecular Sciences 2011 in Orlando, Florida, PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment,will be showcasing several new drug discovery technologies and applications - including new products based on Alpha technology and a novel panel ofepigenetics-based detection reagents.

According to Martina Bielefeld-Sévigny, Ph.D., vice president and general manager, Drug Discovery and Research Reagent Solutions, Bio-discovery, PerkinElmer, “PerkinElmer provides researchers in drug discovery and life sciences with the ability to approach targets from multiple perspectives; to locate, detect and quantifytheir targets of interest, to analyze and understand them in wider physiological contexts. Our ability to deliver reagents, instruments, knowledge and services, helps advance research and drug discovery with the translational data and analysis to help lead to breakthrough insights.”

PerkinElmer's SBS offerings will include the Company's expanded epigenetic detection reagents specifically validated for drug discovery and life sciences research for disease states including cancer, neurodegenerative and metabolic disorders, as well as applications for stem cells and immunology.Additionally, PerkinElmer will also feature the EnSpire®Multimode Plate Reader with new optical label-free detection, the first and only benchtop detection platform to combine Corning®Epic®label-free technology and traditional labeled assays to accurately identify and characterize potential new therapeutic targets.This combination of labeled and label-free detection technologies providesresearchers with a more complete and insightful view of their cellular and biochemical interactions.

PerkinElmer’s new technologies and assay expansions on display at SBS Booth 701 include:

PerkinElmer’s epigenetic and post-DNA translational screening tools now cover nine different histone marks as well as p53, with more than 15 validated enzyme assays to help researchers discover novel drug compounds directed against several epigenetic enzymes, such as histone methyltransferases (HMTs), demethylases (HDMs), acetyltransferases (HATs) and deacetylases (HDACs).

AdditionalPerkinElmerproducts on displayat SBS Booth 701 will include:

PerkinElmer’s Full DayInteractiveWorkshop

Well to Cell and Beyond - Widen the Physiological Perspective

Sunday, March 27, 9:00 a.m. – 4:30 p.m., Gaylord Palms Resort and Convention Center, Naples Room (Complimentary lunch included)

Join colleagues from pharmaceutical discovery and academia to learn about experiences with emerging technologies used for studying the cell signaling continuum in entirely new ways. A series of user presentations will offer an overview of leading solutions and novel techniques being applied to aid in the future of cellular biological research.

Presentations include:

For more information about the PerkinElmer offerings at SBS, including in-booth education, customer workshops, technical posters and presentations, visit www.perkinelmer.com/SBS2011.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Media Contacts:

Amanda L. Connolly
Edelman (On behalf of PerkinElmer, Inc.)
Phone: (404) 832-6785
Email: amanda.connolly@edelman.com